Skip to content

D&A at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$594M-41.3%
Incyte logo
IncyteINCY
$23.8M+6.4%
Immunome logo
ImmunomeIMNM
$603K-1.3%
Arcus Biosciences logo
Arcus BiosciencesRCUS
$2M-33.3%
Celcuity logo
CelcuityCELC
$47K+27.0%
Tango Therapeutics logo
Tango TherapeuticsTNGX
$463K-25.6%

Other financials

Income statement

See full
Revenue$51.8M+30.9%
Operating income$158.0K+101%
Net income-$3.6M+81.6%
EPS (diluted)-$0.01+66.7%

Balance sheet

See full
Cash & equivalents$48.7M-12.2%
Total debt$134.0M+10.0%
Total equity$229.1M-14.6%
Total assets$534.1M-5.0%

Cash flow

See full
Operating cash flow-$62.9M-31.1%
CapEx$206.0K+2.0%
Free cash flow-$43.8M-6.8%

Valuation

See full
Market cap$888.51M-8.6%
Enterprise value$973.78M-6.2%
P/S4.7×-174×

Profitability

See full
Operating margin-705.5%-351pp
Net margin-682.5%-339pp
FCF margin-734.4%-365pp

Returns & leverage

See full
Return on equity-27.1%-7.8pp
Debt / equity0.6×+0.1×
Current ratio6.8×-1.1×

Where this comes from

Reported directly by Geron in its filing.

Tagged under the XBRL concept us-gaap:DepreciationAndAmortization.

The official record: Geron’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Geron's d&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Geron's D&A?
Geron (GERN) reported D&A of $134K in Q1 2026.
How has Geron's D&A changed year-over-year?
Geron's D&A increased by 2.3% year-over-year, from $131K to $134K.
What is the long-term trend for Geron's D&A?
Over 4 years (2021 to 2025), Geron's D&A has grown at a 21.9% compound annual growth rate (CAGR), from $215K to $474K.
What does D&A mean?
Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.